Rallybio Corp Total Liabilities
Rallybio Corp total liabilities. Based on the latest financial reports, Rallybio Corp (RLYB) has total liabilities worth $3.57 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Rallybio Corp liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Rallybio Corp (2019–2025)
Total liabilities of Rallybio Corp from 2019 to 2025. This chart illustrates how Rallybio Corp's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Rallybio Corp's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Rallybio Corp Competitors by Total Liabilities
The table below lists competitors of Rallybio Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Biotalys NV
BR:BTLS
|
Belgium | €9.18 Million |
|
NH All One REIT Co Ltd
KO:400760
|
Korea | ₩723.86 Billion |
|
Unique Engineering and Construction Public Company Limited
BK:UNIQ
|
Thailand | ฿35.14 Billion |
|
Viet Nam Power Development JSC
VN:VPD
|
Vietnam | ₫361.15 Billion |
|
Pylon Public Company Limited
BK:PYLON
|
Thailand | ฿467.28 Million |
|
Demco Public Company Limited
BK:DEMCO
|
Thailand | ฿2.35 Billion |
|
Escar Turizm Tasimacilik Ticaret AS
IS:ESCAR
|
Turkey | TL3.63 Billion |
|
S 11 Group Public Company Limited
BK:S11
|
Thailand | ฿2.94 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Rallybio Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Rallybio Corp (RLYB) total assets.
Liquidity & Leverage Metrics
Rallybio Corp Total Liabilities Ratios Explained
Rallybio Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 27.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rallybio Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rallybio Corp (2019–2025)
The table below shows the annual total liabilities of Rallybio Corp from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.30 Million | -33.30% |
| 2024-12-31 | $6.45 Million | -31.60% |
| 2023-12-31 | $9.44 Million | -15.13% |
| 2022-12-31 | $11.12 Million | +68.89% |
| 2021-12-31 | $6.58 Million | +12.43% |
| 2020-12-31 | $5.86 Million | +23.34% |
| 2019-12-31 | $4.75 Million | -- |
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical … Read more